Abstract
Primary tumor location is considered as a predictive factor of first-line targeted therapies of anti-VEGF antibody, bevacizumab (BEV) or anti-EGFR antibody, cetuximab (CET) panitumumab (PAN) in patients with RAS wild-type and metastatic colorectal cancer (mCRC). However, this is based on the post-hoc analyses of clinical trials and there is a lack of real-world evidence. We conducted a multi-center retrospective study to evaluate the efficacy of BEV and CET/PAN according to the primary tumor location.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
